GAO Jie, WU Hai-wang, DU Xin, et al. Orthogonal Design Method to Study Optimal Ratio of Hydroxyurea and Mifepristone in Miscarriage Models of Rats[J]. Chinese journal of experimental traditional medical formulae, 2016, 22(16): 114-118.
DOI:
GAO Jie, WU Hai-wang, DU Xin, et al. Orthogonal Design Method to Study Optimal Ratio of Hydroxyurea and Mifepristone in Miscarriage Models of Rats[J]. Chinese journal of experimental traditional medical formulae, 2016, 22(16): 114-118. DOI: 10.13422/j.cnki.syfjx.2016160114.
Orthogonal Design Method to Study Optimal Ratio of Hydroxyurea and Mifepristone in Miscarriage Models of Rats
Objective: To screen optimal ratio of hydroxyurea and mifepristone of kidney deficiency and luteum inhibition models of miscarriage rats. Method: After cohabitating 100 female SD rats and 50 male rats
there were 9 subjects according to the orthogonal table L9 (34) design. In addition to this
control group (normal saline) was added. Therefore
there were 10 groups altogether. Beginning with first day of pregnancy
the control group was administered with distilled water while other groups were administered with hydroxyurea according to orthogonal design table. All weights of the rats were measured in the 1st
4th
9th day after mating. During the 10th day
all groups were administered with mifepristone according to orthogonal design table except the control group. Then observed the general conditions of the rats
measured the weights
embryo diameter
calculated the miscarriage rate. Result: The embryo diameter of model group 1-4
6-8 decreased significantly (P<0.05) comparing with control group during the 11th day of pregnancy. The miscarriage rate of model group 1-9 increased significantly (P<0.05) comparing with control group during the 11th day of pregnancy. Therefore
mifepristone is more of contribution than hydroxyurea in miscarriage rate and embryo diameter. Conclusion: The miscarriage rate and embryo diameter are as the core indicators to evaluate pregnant rats and to screen the optimal ratio of hydroxyurea and mifepristone of model group 2